NCT06774781 Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions
| NCT ID | NCT06774781 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Prostate Cancer (Adenocarcinoma) |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2021-10-23 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2021-10-23 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to assess the chance to predict prostate cancer with the analysis of specific values found in images obtained from RMmp (multiparametric magnetic resonance imaging) of patients who went through the procedure at IRCCS Azienda Ospedaliero-Universitaria hospital in the city of Bologna from September 2015 to March 2021. The main question it aims to answer is: \- does the analysis of ADC values and radiomics values found in the RMmp images help with the detection of prostate cancer?
Eligibility Criteria
Inclusion Criteria: * Presence of one or more lesions classified as PI-RADSv2.1 ≥ 3 at a prostate RMmp at the IRCCS Azienda Ospedaliero-Universitaria in Bologna * Indication for eco-guided targeted biopsy by fusion technique integrated with systematic biopsy * Indication for radical prostatectomy * Participants aged 18 at the time of examination * Obtaining informed consent. Exclusion Criteria: * Impossibility of performing MRI (claustrophobic or obese participants etc.) or contraindications to the execution of MRI * Technically sub-optimal investigations for the presence of artifacts (hip prosthesis, movement of the endorectal probe, etc.)
Contact & Investigator
Caterina Gaudiano, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06774781 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer (Adenocarcinoma). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06774781 currently recruiting?
Yes, NCT06774781 is actively recruiting participants. Contact the research team at caterina.gaudiano@aosp.bo.it for enrollment information.
Where is the NCT06774781 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06774781 clinical trial?
NCT06774781 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Caterina Gaudiano, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.